Vir Biotechnology, Inc. Other Comprehensive Income (Loss), Net of Tax
Vir Biotechnology, Inc. (VIR) reported Other Comprehensive Income (Loss), Net of Tax of -$340.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-02-23
- Vir Biotechnology, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-03-31 was -$258.00K.
- Vir Biotechnology, Inc. other comprehensive income (loss), net of tax for the quarter ending 2024-12-31 was -$2.84M, a 362.12% decline year-over-year.
- Vir Biotechnology, Inc. other comprehensive income (loss), net of tax for the quarter ending 2024-09-30 was $4.01M, a 299.40% increase year-over-year.
- Vir Biotechnology, Inc. other comprehensive income (loss), net of tax for the quarter ending 2024-06-30 was -$482.00K, a 252.53% decline year-over-year.
- Vir Biotechnology, Inc. other comprehensive income (loss), net of tax for fiscal 2025 was -$340.00K.
- Vir Biotechnology, Inc. other comprehensive income (loss), net of tax for fiscal 2024 was -$902.00K, a 110.86% decline from fiscal 2023.
- Vir Biotechnology, Inc. other comprehensive income (loss), net of tax for fiscal 2023 was $8.31M.
- Vir Biotechnology, Inc. other comprehensive income (loss), net of tax for fiscal 2022 was -$8.02M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$340.00K 10-K · filed 2026-02-23 | |||
| 2025-03-31 | -$258.00K 10-Q · filed 2025-05-08 | -$3.10M derived: sum of 2 quarters · filed 2026-02-23 | $904.00K derived: sum of 3 quarters · filed 2026-02-23 | $422.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-12-31 | -$2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.16M derived: sum of 2 quarters · filed 2026-02-23 | $680.00K derived: sum of 3 quarters · filed 2026-02-23 | -$902.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | $4.01M 10-Q · filed 2024-11-04 | $3.52M derived: sum of 2 quarters · filed 2024-11-04 | $1.94M 10-Q · filed 2024-11-04 | $3.03M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$482.00K 10-Q · filed 2024-08-01 | -$2.06M 10-Q · filed 2024-08-01 | -$979.00K derived: sum of 3 quarters · filed 2026-02-23 | $24.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | -$1.58M 10-Q · filed 2025-05-08 | -$497.00K derived: sum of 2 quarters · filed 2026-02-23 | $506.00K derived: sum of 3 quarters · filed 2026-02-23 | $822.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $2.09M derived: sum of 2 quarters · filed 2026-02-23 | $2.40M derived: sum of 3 quarters · filed 2026-02-23 | $8.31M 10-K · filed 2026-02-23 |
| 2023-09-30 | $1.00M 10-Q · filed 2024-11-04 | $1.32M derived: sum of 2 quarters · filed 2024-11-04 | $7.22M 10-Q · filed 2024-11-04 | |
| 2023-06-30 | $316.00K 10-Q · filed 2024-08-01 | $6.22M 10-Q · filed 2024-08-01 | ||
| 2022-12-31 | -$8.02M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |